Navigation Links
Common alternative treatment for liver disease is found to be ineffective

Results of high-quality randomized clinical trials have determined that milk thistle extract, a widely used alternative medication, may not have any significant influence on the course of patients with alcoholic liver disease or hepatitis B or C liver disease. These findings are published in The American Journal of Gastroenterology.

According to the previous studies, milk thistle extracts have been shown to possess properties that protect against various hepatotoxins, including the prevention of lipid perioxidation, which is frequent in all stages of liver damage in alcoholic and non-alcoholic liver disease.

"The ironic fact is," notes Christian Gluud of the Copenhagen Trial Unit, Center for Clinical Intervention Research at the Copenhagen University Hospital, "that even though milk thistle and milk thistle extracts have been widely examined, we are still not in a situation where we can exclude a potential beneficial or harmful effect."

In this study, researchers aimed to determine the exact benefits or harm in using milk thistle to treat affected patients. Over 900 patients with the aforementioned types of liver disease were studied in these trials over a period of six months, in groups treated with milk thistle versus placebo treatment. No significant effects were observed on mortality or complication of the disease. Further, milk thistle was not associated with any significant risk of adverse events.

"It would be logical to stop the use of milk thistle products, not to reimburse any use, to stop the information that milk thistle products may be used, and to support further trials," adds Gluud.


'"/>

Source:Blackwell Publishing Ltd.


Page: 1

Related biology news :

1. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
2. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
3. Men Estimate Mens Risks Of Common Disorders Higher Than Women Do, And Vice Versa
4. Use of Antibiotics for Acne May Increase Risk of Common Illness
5. Common viruses may cause cancer
6. Common molecular signature identified in solid tumors
7. Common bacteria pirate natural mechanism to get inside cells
8. Commonly used antidepressants may also affect human immune system
9. Common practices at petting zoos put visitors at risk
10. Common enzyme is a key player in DNA repair
11. Common molecular signature identified in solid tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ -  Equicare Health Inc ., ... been recognized as one of the top 100 companies ... international listing that distinguishes the top digital health companies ... great step forward this year continually upgrading our product ... customer base and team," says Len Grenier , ...
(Date:11/30/2016)... 2016 Part of 5m$ Investment in ... ... Aptuit, LLC today announced that it had successfully completed the ... compounds have increased the Screening Collection to over 400,000. The ... capabilities of the company. This expansion, complemented by new robotics ...
(Date:11/30/2016)... ... November 30, 2016 , ... T3D Therapeutics, Inc., a ... administered treatment for Alzheimer’s disease (AD), today announced that CEO, John Didsbury, will ... of T3D-959 in mild to moderate Alzheimer’s patients at CTAD 2016. Preliminary results ...
(Date:11/30/2016)... ... November 30, 2016 , ... Microbial genomics leader uBiome will ... Huffington, as part of the Thrive Global pop-up store. This stunning 5,000 square ... explore the microorganisms in their gut, collectively known as the microbiome. , The ...
Breaking Biology Technology: